×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:AZN

AstraZeneca Stock Forecast, Price & News

$65.93
-0.58 (-0.87%)
(As of 06/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$65.58
$66.61
50-Day Range
$59.26
$68.85
52-Week Range
$53.63
$71.70
Volume
7.35 million shs
Average Volume
7.34 million shs
Market Capitalization
$204.31 billion
P/E Ratio
N/A
Dividend Yield
2.90%
Price Target
$62.00
30 days | 90 days | 365 days | Advanced Chart

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock Forecast (MarketRank)

Overall MarketRank

2.13 out of 5 stars

Medical Sector

462nd out of 1,433 stocks

Pharmaceutical Preparations Industry

198th out of 685 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
AstraZeneca logo

About AstraZeneca (NASDAQ:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock News Headlines

These 3 Nasdaq-100 Leaders Have More Upside (AZN)
Through June 24th, all but 16 of the popular benchmark’s names were in the red for 2022. At the other end of the spectrum is an unlikely collection of stocks that have boldly bucked the market trend. The upside in these three Nasdaq-100 stocks has only begun.
AstraZeneca BrandVoice - Forbes
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZN
Employees
83,100
Year Founded
1999

Company Calendar

Last Earnings
4/29/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$8,246.29
High Stock Price Forecast
$12,000.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
-6.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
12 Analysts

Profitability

Net Income
$112 million
Pretax Margin
-3.18%

Debt

Sales & Book Value

Annual Sales
$37.42 billion
Cash Flow
$4.48 per share
Book Value
$12.68 per share

Miscellaneous

Outstanding Shares
3,098,840,000
Free Float
N/A
Market Cap
$204.31 billion
Optionable
Optionable
Beta
0.45

Social Links















AstraZeneca Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AstraZeneca stock.
View analyst ratings for AstraZeneca
or view top-rated stocks.

What is AstraZeneca's stock price forecast for 2022?

12 Wall Street analysts have issued 1-year target prices for AstraZeneca's shares. Their AZN stock forecasts range from $54.00 to $12,000.00. On average, they anticipate AstraZeneca's stock price to reach $8,246.29 in the next twelve months. This suggests a possible upside of 12,407.6% from the stock's current price.
View analysts' price targets for AstraZeneca
or view top-rated stocks among Wall Street analysts.

How has AstraZeneca's stock price performed in 2022?

AstraZeneca's stock was trading at $58.25 at the beginning of 2022. Since then, AZN stock has increased by 13.2% and is now trading at $65.93.
View the best growth stocks for 2022 here
.

Are investors shorting AstraZeneca?

AstraZeneca saw a increase in short interest in June. As of June 15th, there was short interest totaling 14,760,000 shares, an increase of 36.2% from the May 31st total of 10,840,000 shares. Based on an average daily volume of 7,090,000 shares, the days-to-cover ratio is presently 2.1 days.
View AstraZeneca's Short Interest
.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for AstraZeneca
.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) announced its earnings results on Friday, April, 29th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.09. The business had revenue of $11.39 billion for the quarter, compared to analysts' expectations of $10.96 billion. AstraZeneca had a positive trailing twelve-month return on equity of 25.35% and a negative net margin of 2.56%. The firm's quarterly revenue was up 55.6% on a year-over-year basis. During the same period last year, the company posted $0.81 earnings per share.
View AstraZeneca's earnings history
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Friday, February 11th. Investors of record on Friday, February 25th will be given a dividend of $0.985 per share on Monday, March 28th. This represents a yield of 2.4%. The ex-dividend date of this dividend is Thursday, February 24th. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.45.
View AstraZeneca's dividend history
.

Is AstraZeneca a good dividend stock?

AstraZeneca(NASDAQ:AZN) pays an annual dividend of $1.93 per share and currently has a dividend yield of 2.90%.
View AstraZeneca's dividend history.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 63, Pay $5.85M)
  • Dr. Aradhana Sarin M.D., CFO & Exec. Director (Age 47, Pay $4.32M)
  • Mr. Marc Dunoyer, CEO of Alexion & Chief Strategy Officer (Age 70, Pay $2.05M)
  • Ms. Pam P. Cheng, EVP of Operations & Information Technology and Member of External Sustainability Advisory Board (Age 51)
  • Mr. Chris Sheldon, Head of Investor Relations
  • Mr. Jeffrey Pott, EVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Ms. Katarina Ageborg, EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
  • Gonzalo Vina, Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D., EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board (Age 55)
  • Dr. Ruud Dobber Ph.D., Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

1,263 employees have rated AstraZeneca CEO Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among AstraZeneca's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AstraZeneca own?

What is AstraZeneca's stock symbol?

AstraZeneca trades on the NASDAQ under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (1.51%), Primecap Management Co. CA (1.49%), Capital International Investors (1.19%), Fisher Asset Management LLC (0.67%), GQG Partners LLC (0.59%) and Bank of America Corp DE (0.36%).
View institutional ownership trends for AstraZeneca
.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, Renaissance Technologies LLC, GQG Partners LLC, Dimensional Fund Advisors LP, Bank of Montreal Can, Neuberger Berman Group LLC, Federated Hermes Inc., and Wellington Management Group LLP.
View insider buying and selling activity for AstraZeneca
or view top insider-selling stocks.

Which institutional investors are buying AstraZeneca stock?

AZN stock was bought by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, 1832 Asset Management L.P., Farallon Capital Management LLC, Capital International Investors, Ensign Peak Advisors Inc, BlackRock Inc., Twin Tree Management LP, and ProShare Advisors LLC.
View insider buying and selling activity for AstraZeneca
or or view top insider-buying stocks.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $65.93.

How much money does AstraZeneca make?

AstraZeneca (NASDAQ:AZN) has a market capitalization of $204.31 billion and generates $37.42 billion in revenue each year. The company earns $112 million in net income (profit) each year or ($0.320010) on an earnings per share basis.

How many employees does AstraZeneca have?

AstraZeneca employs 83,100 workers across the globe.

Does AstraZeneca have any subsidiaries?

The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Inc., AstraZeneca Pharmaceuticals (Pty) Limited, AstraZeneca Pharmaceuticals Aktiebolag, AstraZeneca Pharmaceuticals Co. Limited, AstraZeneca Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, AstraZeneca Pharmaceuticals Limited, AstraZeneca Pharmaceuticals Pakistan (Private) Limited, AstraZeneca Pharmaceuticals Technologies (Beijing) Co. Ltd, AstraZeneca Produtos Farmaceuticos Lda, AstraZeneca Quest Limited, AstraZeneca Rho B.V., AstraZeneca S.A., AstraZeneca S.A. / N.V., AstraZeneca S.A. de C.V., AstraZeneca S.A.S., AstraZeneca Sdn Bhd, AstraZeneca Share Trust Limited, AstraZeneca Sigma B.V., AstraZeneca Singapore Pte Limited, AstraZeneca SpA, AstraZeneca Sweden Investments Limited, AstraZeneca Södertälje 2 AB, AstraZeneca Taiwan Limited, AstraZeneca Treasury B.V., AstraZeneca Treasury Limited, AstraZeneca Tunisie SaRL, AstraZeneca UK Limited, AstraZeneca US Investments Limited, AstraZeneca Ukraina LLC, AstraZeneca Venezuela S.A., AstraZeneca Vietnam Company Limited, AstraZeneca Zeta B.V, AstraZeneca d.o.o, AstraZeneca do Brasil Limitada, AstraZeneca Österreich GmbH, Atkemix Nine Inc., Atkemix Ten Inc., BMS Holdco Inc., Cambridge Antibody Technology, Cambridge Antibody Technology Group Limited, Centus Biotherapeutics Limited, Corpus Christi Holdings Inc., Definiens GmbH, Definiens Inc., Drimex LLC, Gotland Pharma S.A., Guangdong BeiKang Pharmaceutical Company Ltd, IPR Pharmaceuticals Inc., KuDOS Horsham Limited, KuDOS Pharmaceuticals Limited, KuDOS Pharmaceuticals Ltd, Laboratorio Beta S.A., Laboratorio Lailan S.A., Laboratorio Odin S.A., Laboratorio Tau S.A., MedImmune LLC, MedImmune Limited, MedImmune Pharma B.V, MedImmune U.K. Limited, MedImmune Ventures Inc, Montrose Chemical Corporation of California, Novastra Promoção e Comércio Farmacêutico Lda, Novastuart Produtos Farmaceuticos Lda, Novexel, Omthera Pharmaceuticals, Omthera Pharmaceuticals Inc., Optein Inc., P.T. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos .
Read More

When was AstraZeneca founded?

AstraZeneca was founded in 1999.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The official website for AstraZeneca is www.astrazeneca.com. The company can be reached via phone at 442037495000, via email at [email protected], or via fax at 44-12-2335-2858.

This page (NASDAQ:AZN) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.